JAMP Pharma Corporation is recalling one lot of JAMP Guanfacine extended release (XR) 1 mg tablets because some bottles may contain JAMP Guanfacine XR 4 mg tablets in addition to the correct strength of 1 mg tablets. Patients taking a 4 mg tablet instead of a prescribed 1 mg tablet will unexpectedly receive a higher dose than intended, which may result in overdose and could pose serious health risks. JAMP Guanfacine XR is a prescription drug used to treat Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents 6 to 17 years of age. The 1 mg tablet is white and round with the letters 'GNF' stamped on one side and '1MG' stamped on the other. The 4 mg tablet is green and oval with the letters 'GNF' stamped on one side and '4MG' stamped on the other. Signs and symptoms of guanfacine overdose may include hypertension (high blood pressure), hypotension (low blood pressure), bradycardia (slow heartbeat) or abnormal heart rhythms, lethargy (drowsiness/feeling tired), respiratory depression (slowed breathing), or coma (loss of consciousness). It may take up to 24 hours for signs and symptoms of overdose to appear after taking too much of the product. Patients with suspected overdose should consult their health care professional immediately, as they may require monitoring in hospital. Health Canada is monitoring the company's recall, and its implementation of any necessary corrective and preventative actions to stop this issue from reoccurring. The Department will inform the public if any new health risks are identified.
RecallTracker